Effect of supplementation in treatment of patients with multiple sclerosis
Phase 2
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT201609185623N88
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with multiple sclerosis
Aged 18 to 55 years
Course of disease relapsing–remitting MS (RRMS)
EDSS =4.5
Exclusion Criteria
Pregnancy
Women who were lactating within the prior six month
Consumption of of probiotic or synbiotic
Menopaused women with irregular menstruation
Unwillingness to utilize appropriate contraceptive tools
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin 1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin-8. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.
- Secondary Outcome Measures
Name Time Method Peroxisome proliferator–activated receptor ? (PPAR?). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Low Density Lipoprotein Receptor (LDLR). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.